Galectin Therapeutics

GALTNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$408.441 M

$4.05 -2.17%

Close of 23 Sept 2026

Revenue

—

Not reported

Earnings

-$30.8M

Loss-making

Shares outstanding

100,849,644

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 500 →

#212Atea PharmaceuticalsAVIR$423.5M
#213ARS PharmaceuticalsSPRY$415.7M
#214Galectin TherapeuticsGALT$408.4M
#215DiaMedica TherapeuticsDMAC$407.7M
#216Relmada TherapeuticsRLMD$403.2M

What if Galectin Therapeutics were worth as much as…

Open the what-if tool →

Gold $29.8T

$295,954.71

Per share 73,075× higher

Bitcoin $1.69T

$16,798.48

Per share 4,148× higher

Nvidia $5.43T

$53,890.04

Per share 13,306× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for Galectin Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 24 Sept 2026. Read the methodology.